Celcuity (CELC) Capital Expenditures (2016 - 2025)
Celcuity's (CELC) quarterly Capital Expenditures came in at $53000.0 in Q4 2025, up 17.78% YoY from $45000.0 in Q4 2024, and down 45.36% on a QoQ basis from $97000.0 in Q3 2025.
Celcuity (CELC) Capital Expenditures (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Capital Expenditures data on file, last reported at $53000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 17.78% year-over-year to $53000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $249000.0 (changed 0.4% YoY) and the FY2025 annual result came in at $249000.0, changed 0.4% from the prior year.
- Capital Expenditures retreated to $53000.0 in Q4 2025, from $97000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $112044.0 in Q4 2022 to a low of $4854.0 in Q2 2023.
- A 5-year average of $41865.5 and a median of $35849.5 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 78.88% — and 2024, when it soared 1218.5%.
- Tracing CELC's Capital Expenditures over 5 years: stood at $9939.0 in 2021, then soared by 1027.32% to $112044.0 in 2022, then tumbled by 70.82% to $32699.0 in 2023, then surged by 37.62% to $45000.0 in 2024, then rose by 17.78% to $53000.0 in 2025.
- The last three Capital Expenditures figures came in at $53000.0 (Q4 2025), $97000.0 (Q3 2025), and $39000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53,000.00 |
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Sep 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Sep 30, 2024 | 51,000.00 |
| Sep 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 90,000.00 |
| Mar 31, 2024 | 90,000.00 |
| Dec 31, 2023 | 32,699.00 |
| Dec 31, 2023 | 32,699.00 |
| Sep 30, 2023 | 53,104.00 |
| Sep 30, 2023 | 53,104.00 |